Acorda Therapeutics (NASDAQ:ACOR) announced this morning the safety and tolerability data from its Phase 1 clinical trial of rHIgM22, a remyelinating antibody, which is …
In a research report issued today, J.P.
In a research note released yesterday, Canaccord Genuity analyst John Newman maintained a Hold rating on Acorda Therapeutics (ACOR) and reduced his price …
